Willi Oberaigner1, Uwe Siebert. 1. Cancer Registry of Tyrol, Department of Clinical Epidemiology of the Tyrolean State Hospitals Ltd, Innsbruck, Austria. willi.oberaigner@iet.at
Abstract
BACKGROUND: Gender aspects in medicine are receiving increasing attention, namely also in oncology. For this reason, we decided to investigate whether for solid cancer sites women have better survival outcome than do men in the population of Tyrol, Austria. METHODS: We conducted an observational population-based study in Tyrol. All solid cancer sites excluding non-melanoma skin cancer and sex-specific sites were analysed in total and all specific sites with more than 500 patients in the analysis. By the end of 2006, follow-up was ended. We applied a relative excess risk model, thus correcting for differences in life expectancy between women and men. RESULTS: For all cancer sites combined, after adjusting for case mix, women had a relative excess risk of 0.95 (95% CI 0.91-0.99). For the following sites our analysis resulted in a relative excess risk statistically different from 1, namely for women as compared to men: head and neck without larynx 0.72 (95% CI 0.56-0.93), stomach 0.86 (95% CI 0.75-0.97) and lung 0.82 (95% CI 0.75-0.90). CONCLUSION: In a healthcare system with free access to diagnostics and therapy, after adjusting for staging distribution female cancer patients have a lesser excess mortality risk than do men for lung, stomach and head and neck cancer and also for all cancer sites combined after adjusting for case mix.
BACKGROUND: Gender aspects in medicine are receiving increasing attention, namely also in oncology. For this reason, we decided to investigate whether for solid cancer sites women have better survival outcome than do men in the population of Tyrol, Austria. METHODS: We conducted an observational population-based study in Tyrol. All solid cancer sites excluding non-melanoma skin cancer and sex-specific sites were analysed in total and all specific sites with more than 500 patients in the analysis. By the end of 2006, follow-up was ended. We applied a relative excess risk model, thus correcting for differences in life expectancy between women and men. RESULTS: For all cancer sites combined, after adjusting for case mix, women had a relative excess risk of 0.95 (95% CI 0.91-0.99). For the following sites our analysis resulted in a relative excess risk statistically different from 1, namely for women as compared to men: head and neck without larynx 0.72 (95% CI 0.56-0.93), stomach 0.86 (95% CI 0.75-0.97) and lung 0.82 (95% CI 0.75-0.90). CONCLUSION: In a healthcare system with free access to diagnostics and therapy, after adjusting for staging distribution female cancerpatients have a lesser excess mortality risk than do men for lung, stomach and head and neck cancer and also for all cancer sites combined after adjusting for case mix.
Authors: M D Chirlaque; D Salmerón; J Galceran; A Ameijide; A Mateos; A Torrella; R Jiménez; N Larrañaga; R Marcos-Gragera; E Ardanaz; M Sant; P Minicozzi; C Navarro; M J Sánchez Journal: Clin Transl Oncol Date: 2017-07-17 Impact factor: 3.405
Authors: Kevin D Boyd; Fiona M Ross; Laura Chiecchio; GianPaolo Dagrada; Zoe J Konn; William J Tapper; Brian A Walker; Christopher P Wardell; Walter M Gregory; Alex J Szubert; Faith E Davies; Gareth J Morgan Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-06-15 Impact factor: 4.254
Authors: Marie-Pier Bergeron-Boucher; Jim Oeppen; Niels Vilstrup Holm; Hanne Melgaard Nielsen; Rune Lindahl-Jacobsen; Maarten Jan Wensink Journal: Int J Environ Res Public Health Date: 2019-08-26 Impact factor: 3.390
Authors: Ping Ching Pai; Chi Cheng Chuang; Wen Ching Chuang; Ngan Ming Tsang; Chen Kan Tseng; Kuan Hung Chen; Tzu Chen Yen; Chien Yu Lin; Kai Ping Chang; Kin Fong Lei Journal: Cancer Med Date: 2018-04-02 Impact factor: 4.452
Authors: Sarah Bird; David Cairns; Tom Menzies; Kevin Boyd; Faith Davies; Gordon Cook; Mark Drayson; Walter Gregory; Matthew Jenner; John Jones; Martin Kaiser; Roger Owen; Graham Jackson; Gareth Morgan; Charlotte Pawlyn Journal: Clin Lymphoma Myeloma Leuk Date: 2021-04-24